Form 4: Alignment Healthcare CEO John Kao Sells Shares to Cover Tax Obligations and Under 10b5-1 Plan

Sentiment:

SEC Form 4 Filing


Alignment Healthcare's CEO, John Kao, executed multiple sales of common stock, including transactions to cover tax withholding obligations and sales under a pre-arranged 10b5-1 trading plan.

Summary

  • John Kao, CEO of Alignment Healthcare, reported several transactions involving the company's common stock.
  • On March 11, 2025, Kao sold 89,900 shares at a weighted-average price of $15.3577, with individual prices ranging from $14.72 to $15.69.
  • An additional 100 shares were sold on the same day at $15.72.
  • On March 12, 2025, Kao sold 52,372 shares at a weighted-average price of $15.4231, with individual prices ranging from $14.72 to $15.715, to cover tax withholding obligations related to vesting restricted stock units.
  • Another 750 shares were sold on March 12, 2025, at a weighted-average price of $15.7379, with individual prices ranging from $15.72 to $15.76.
  • Some of the sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2024.
  • Following these transactions, Kao directly owns 4,680,542 shares and indirectly owns 2,093,100 shares through the JEK Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions appear to be routine sales for tax purposes and part of a pre-planned trading arrangement. There's no indication of a significant shift in management's confidence.

Industry Context

Insider sales are a common occurrence, especially when related to tax obligations or pre-planned trading arrangements like 10b5-1 plans. Investors often monitor these transactions for insights into management's perspective on the company's value, but sales for tax purposes are generally viewed as less informative.

Stakeholder Impact

  • The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market.
  • The impact is likely to be minimal as the sales are related to tax obligations and a pre-arranged trading plan.

Key Dates

DateDescription
2021-02-08Date of JEK Trust
2024-03-14Date of Rule 10b5-1 plan adoption
2025-03-11Date of stock sales
2025-03-12Date of stock sales
2025-03-13Date of signature

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.